Our Strategy

At Liminal, we have developed a strategy to build a broader portfolio of novel small molecule compounds over time and explore opportunities for collaboration in our small molecule development programs.

Advancing the clinical development of our small molecule pipeline candidates

Fezagepras, our lead candidate, has been proven in pre-clinical models to be an anti-inflammatory and anti-fibrotic agent. In December 2020, fezagepras entered a Phase 1 multi-ascending dose clinical trial in the UK to evaluate multiple-ascending doses (MAD) in normal healthy volunteers, at daily dose exposures higher than those evaluated in our previously completed Phase 2 clinical trials.

The Company has completed the clinical phase of its Phase 1 multi-ascending dose (“MAD”) clinical trial and is in the process of evaluating the complete pharmacokinetic (“PK”) data set from the Phase 1 MAD clinical trial and expects to complete this analysis before the end of the fourth quarter of 2021. The Company anticipates updating the market on any further development plans for fezagepras during the first quarter of 2022.

Our early-stage drug development efforts are focused on expanding our R&D pipeline both for the treatment of diseases associated with fibrosis and for other inflammatory diseases. Accordingly, alongside fezagepras, we intend to develop oral, selective GPR84 antagonists to treat fibrosis, primarily for patients with respiratory and renal disease. GPR84 is a pro-inflammatory target primarily expressed on cells associated with the immune system and its expression levels increase significantly during periods of inflammatory stress.

In addition to GRP84, we intend to develop a novel, selective OXER1 antagonist candidate. OXER1 is a GPCR that is highly selective for 5-oxo-ETE, believed to be one of the most potent human eosinophil chemo-attractants. Eosinophils play a key role in Type 2 inflammation-driven diseases, including respiratory diseases and gastrointestinal diseases. Our GPR84 antagonist and OXER1 antagonist R&D programs are currently both at the pre-clinical research stage.